The next best thing to Mounjaro, according to the clinical evidence

What the head-to-head trial showed about Mounjaro versus its closest rival

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, is the most relevant piece of evidence for anyone asking this question. It enrolled 751 adults with obesity but without type 2 diabetes, ran for 72 weeks, and directly compared tirzepatide against semaglutide 2.4mg, the established maintenance dose of Wegovy. Tirzepatide produced greater average weight loss. That's the clean, trial-level finding.

Why the gap? Mounjaro targets two receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1, and if you're wondering whether Mounjaro and tirzepatide are actually the same thing, the short answer is yes, tirzepatide is the active ingredient in Mounjaro. The dual action appears to drive stronger appetite suppression and, in trial conditions, greater overall weight reduction. NICE cited this indirect and direct evidence when recommending tirzepatide for adults meeting specific BMI and comorbidity criteria in Technology Appraisal TA1026, published December 2024.

There is a common assumption that the gap between these two medicines is small and mainly about marketing. The trial data doesn't support that reading. At the same time, Wegovy's own STEP 1 results (around 15% average weight reduction over 68 weeks) are clinically substantial. For some people, semaglutide is a genuinely strong option, and for a meaningful number of patients it may be the more appropriate clinical choice. That judgement belongs with a prescriber who knows your full history, not a comparison article.

Wegovy injection and the newer oral tablet, where they sit in the picture

Wegovy as an injection has been UK-licensed for weight management for several years, with a well-established titration pathway from 0.25mg up to 2.4mg. A higher 7.2mg maintenance dose, delivered via a dedicated single-dose pen, was approved by the MHRA on 14 April 2026 for adults with a BMI of 30 or above. Early trial data for the 7.2mg dose reported around 20.7% average weight loss over 72 weeks, a figure that narrows the gap with tirzepatide at 15mg considerably. Whether that dose is right for a specific patient is, again, a prescriber's call.

Then there is the oral option. In June 2026 the MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer) as the first oral GLP-1 medicine licensed for weight management in the UK. The OASIS 4 trial reported around 13.6% average weight loss over 64 weeks against placebo, regardless of adherence. For people who prefer a daily tablet to a weekly injection, this is a genuinely new avenue, and you can read more about the full landscape of licensed weight-loss treatments to see how they compare.

None of these are interchangeable without clinical review. Switching between formulations, or starting a new medicine, always requires a prescriber's assessment of your current health, any medications you take and how you've responded to treatment so far.

What actually doesn't come close, and why that matters

A search for 'the next best thing to Mounjaro' will surface a long list of supplements, herbal products and non-prescription weight-loss aids. It's worth saying plainly: none of them have been through the same regulatory process, none hold a UK marketing authorisation for weight management comparable to tirzepatide or semaglutide, and none have produced trial evidence of the same scale or quality. The MHRA has been explicit that GLP-1 medicines are not assessed for quick or cosmetic weight loss, but they are assessed, rigorously, for clinical outcomes. That regulatory bar is what separates licensed medicines from everything else claiming to be in the same category.

For context on the cost of Mounjaro as a private prescription, prices vary between providers and by dose; any legitimate price will include a prescription and clinical assessment. If Mounjaro isn't accessible for you right now, the right next step is a conversation about which licensed option fits your situation, not a detour into unlicensed alternatives.

Orlistat, a lipase inhibitor that blocks absorption of roughly a third of dietary fat, is available in the UK as a prescription or pharmacy medicine. It's mechanistically very different from GLP-1 medicines, produces more modest average results in trials, and is the only other licensed pharmacological option in this country outside the GLP-1 class. It has its place, particularly for people who cannot tolerate injections or are not clinically suitable for GLP-1 treatment. But framing it as a direct substitute for Mounjaro would be misleading.

How a prescriber actually decides between your options

Understanding the evidence is useful context. But the decision itself is clinical. A prescriber will look at your BMI, any existing health conditions, your medication list (some medicines interact with GLP-1 drugs, including certain oral contraceptives during the early weeks of tirzepatide treatment), your weight history and your preferences around injection versus tablet. They will also review whether you have previously tried a GLP-1 medicine and how that went.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally, your answers aren't processed by software. If you're exploring your options, checking your eligibility takes a few minutes and costs nothing. There are no subscriptions, no auto-renewals, and no obligation to proceed.

If you'd like to understand more about how tirzepatide works before going further, the Mounjaro overview covers the mechanism, licensed uses and what a typical treatment course involves. For questions about daily practicalities once you're on treatment, guidance on how to take Mounjaro correctly is worth reading alongside the patient information leaflet your prescriber will supply.